fulvestrant has been researched along with gw9662 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ikeda, K; Xu, JW; Yamori, Y | 1 |
| Glazer, RI; Kopelovich, L; Lu, J; Yin, Y; Yuan, H | 1 |
2 other study(ies) available for fulvestrant and gw9662
| Article | Year |
|---|---|
Genistein inhibits expressions of NADPH oxidase p22phox and angiotensin II type 1 receptor in aortic endothelial cells from stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin II; Anilides; Animals; Aorta, Thoracic; Cells, Cultured; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Fulvestrant; Genistein; Hypertension; Male; Membrane Transport Proteins; NADPH Dehydrogenase; NADPH Oxidases; Phosphoproteins; PPAR gamma; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Signal Transduction; Stroke; Superoxides; Tyrosine; Vasoconstrictor Agents | 2004 |
Drug-targeted inhibition of peroxisome proliferator-activated receptor-gamma enhances the chemopreventive effect of anti-estrogen therapy.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Anilides; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carcinogens; Carcinoma; Chemoprevention; Drug Synergism; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Mammary Neoplasms, Experimental; Mice; Microarray Analysis; Molecular Targeted Therapy; PPAR gamma | 2012 |